Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
8%
Ph phase_2
10
83%
Ph phase_3
1
8%

Phase Distribution

1

Early Stage

10

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
10(83.3%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(7)
Completed(1)
Terminated(1)
Other(3)

Detailed Status

Recruiting4
Not yet recruiting3
unknown3
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 210 (83.3%)
Phase 31 (8.3%)

Trials by Status

completed18%
withdrawn18%
not_yet_recruiting325%
unknown325%
recruiting433%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT07449481Phase 2

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Withdrawn
NCT06764940Phase 2

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Recruiting
NCT06102824Phase 2

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting
NCT06683703Phase 2

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Not Yet Recruiting
NCT06510465Phase 2

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

Not Yet Recruiting
NCT06125080Phase 2

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) :Single-arm, Prospective, Open Clinical Study

Recruiting
NCT05983094Phase 2

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Not Yet Recruiting
NCT05430399Phase 3

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Recruiting
NCT05052437Phase 1

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Completed
NCT05357417Phase 2

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Unknown
NCT05403333Phase 2

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Unknown
NCT05299255Phase 2

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12